(130 days)
Not Found
Not Found
No
The document describes a contact lens cleaning solution and its performance studies. While it mentions "Image Analysis" for evaluating lens cleanliness, there is no indication that this analysis utilizes AI or ML algorithms. The focus is on the chemical composition and cleaning/disinfection efficacy of the solution.
No
The device is a contact lens cleaning and disinfecting solution, not a therapeutic device designed to treat or prevent a disease or condition.
No
Explanation: This device is a contact lens solution used for cleaning, disinfecting, and storing lenses. It does not diagnose any medical condition or disease.
No
The device is a contact lens cleaning solution, which is a chemical product, not a software-only medical device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for cleaning, disinfecting, and storing contact lenses. This is a direct interaction with a medical device (contact lens) and not a test performed in vitro (outside the body) on a biological specimen to diagnose a condition.
- Device Description: The description lists the chemical components of a contact lens solution. This is consistent with a cleaning and disinfecting product, not a diagnostic test.
- Lack of Diagnostic Purpose: There is no mention of the device being used to detect, measure, or analyze any substance in a biological sample for the purpose of diagnosis, monitoring, or screening.
- Performance Studies: The performance studies focus on the safety and efficacy of the solution for cleaning and disinfecting contact lenses, as well as its compatibility with the lenses and its microbiological effectiveness. These are not studies related to diagnostic accuracy.
While the document mentions "Image Analysis for lens cleanliness," this is an evaluation of the device's performance in cleaning the contact lens, not a diagnostic test performed on a patient's sample.
Therefore, the Boston SIMPLUS Multi-Action Solution is a contact lens care product, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Boston SIMPLUS Multi-Action Solution is for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses.
Product codes
MRC
Device Description
Boston SIMPLUS Multi-Action Solution is a sterile, aqueous, buffered solution that contains poloxamine, hydroxyalkylphosphonate, boric acid, sodium borate, sodium chloride, hydroxypropylmethyl cellulose, Glucam and preserved with chlorhexidine gluconate (0.003%), polyaminopropyl biguanide (0.0005%).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
A series of preclinical and clinical studies were completed on Boston SIMPLUS Multi-Action Solution. The results indicate that this product is safe, efficacious, and substantially equivalent to the predicate devices identified in Section 3 of this summary.
Toxicology: A series of in-vitro biological reactivity test were performed to determine the toxicity of Boston SIMPLUS Multi-Action Solution. ISO Agarose Overlay Tests and ISO Ocular Irritation Tests were conducted in accordance with the requirements of ISO 10993-5 and ISO 10993 Part 10 respectively. The test articles demonstrated no evidence of cell lysis and the test solution did not produce significant ocular irritation.
Stability/Sterility: Stability studies were performed to evaluate the effects of various temperatures on the physical, microbiological and chemical properties of various lots of Boston SIMPLUS Multi-Action Solution. All data indicates that the test product meets its specifications.
Cleaning Studies: The cleaning efficacy of Boston SIMPLUS Multi-Action Solution was determined by a series of in-vitro studies.
The Critical Micelle Concentration of the surfactant was evaluated and found acceptable.
Testing was performed to determine the cleaning ability of Boston SIMPLUS Multi-Action Solution on rigid gas permeable contact lenses. A protein and lipid mixture deposition model indicated the test solution cleans equivalently to or better than controls. A tenacious protein deposition model indicated the test solution cleans better than controls.
Lens compatibility studies determined average changes in physical lens parameters were within specifications. Cosmetic appearance of both lens materials tested equivalent to respected controls.
Lenses returned from the clinical study were examined by Image Analysis for lens cleanliness and found to be substantially equivalent.
Microbiology Studies: A series of studies as provided in the Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products were completed to demonstrate the microbiological efficacy of Boston SIMPLUS Multi-Action Solution.
Testing included Preservative Efficacy with Rechallenge, Disinfection Efficacy-Stand Alone, Disinfection Efficacy-Stand Alone with Organic Soil and a Regimen Test. All results are satisfactory and indicate that the product meets FDA/ISO requirements.
Clinical Studies: A multi-site randomized, controlled clinical study was conducted to evaluate the safety and efficacy of Boston SIMPLUS Multi-Action Solution employing a regimen that requires the user to rub lenses after the disinfection cycle. The Control solution was Boston Simplicity Multi-Action Solution traditional rub and rinse steps.
Patients wore lenses daily with no scheduled replacements and cleaned/disinfected according to directions. Evaluations included visual acuity, lens surface characteristics, and physiological response.
Safety endpoint: no statistically significant difference in the incidence rate of any Grade 2 or greater slit lamp findings between Test and Control was satisfied.
Efficacy endpoint: statistical equivalence in the proportion of lens visual acuities at the level of 20/40 or better was met.
Both solutions demonstrated clinically acceptable lens cleanliness. Safety and efficacy were demonstrated.
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Boston Simplicity® Multi-Action Solution, Bausch & Lomb ReNu MultiPlus® Multi-Purpose Solution, Alcon Unique pH
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.5918 Rigid gas permeable contact lens care products.
(a)
Identification. A rigid gas permeable contact lens care product is a device intended for use in the cleaning, conditioning, rinsing, lubricating/rewetting, or storing of a rigid gas permeable contact lens. This includes all solutions and tablets used together with rigid gas permeable contact lenses.(b)
Classification. Class II (Special Controls) Guidance Document: “Guidance for Industry Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products.”
0
510 (k) SUMMARY SUMMARY OF SAFETY AND EFFECTIVENESS
FOR
Boston SIMPLUS Multi-Action Solution
Submitter Information 1.
Polymer Technology A Bausch & Lomb company 1400 North Goodman Street Rochester, New York 14609
| Contact Person: | Jennifer B. Murray |
|---|---|
| Global Regulatory Affairs |
Telephone Number: 585-338-8460
2. Device Name
Classification Name: Rigid Gas Permeable Contact Lens Care Product
Proprietary Name: Boston® SIMPLUS Multi-Action Solution
3. Predicate Devices
Boston Simplicity® Multi-Action Solution, Bausch & Lomb ReNu MultiPlus® Multi-Purpose Solution and Alcon Unique pH were selected as the predicate devices for Boston SIMPLUS Multi-Action Solution.
4. Description of the Device
Boston SIMPLUS Multi-Action Solution is a sterile, aqueous, buffered solution that contains poloxamine, hydroxyalkylphosphonate, boric acid, sodium borate, sodium chloride, hydroxypropylmethyl cellulose, Glucam and preserved with chlorhexidine gluconate (0.003%), polyaminopropyl biguanide (0.0005%).
1
ર્ડ Indications for Use
Boston SIMPLUS Multi-Action Solution is for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses.
Description of Safety and Substantial Equivalence 6.
A series of preclinical and clinical studies were completed on Boston SIMPLUS Multi-Action Solution. The results indicate that this product is safe, efficacious, and substantially equivalent to the predicate devices identified in Section 3 of this summary.
Toxicology
A series of in-vitro biological reactivity test were performed to determine the toxicity of Boston SIMPLUS Multi-Action Solution.
ISO Agarose Overlay Tests of Boston SIMPLUS Multi-Action Solution, Fluoro Silicone Acrylate Lenses Cycled in Boston SIMPLUS Multi-Action Solution and Silicone Acrylate Lenses Cycled in Boston SIMPLUS Multi-Action Solution were conducted in accordance with the requirements of ISO 10993-5. The negative and positive controls performed as anticipated. The test articles demonstrated no evidence of cell lysis. All test requirements were met.
ISO Ocular Irritation Tests of Boston SIMPLUS Multi-Action Solution, extracts of fluoro silicone acrylate lenses cycled in Boston SIMPLUS Multi-Action Solution and extracts of silicone acrylate lenses cycled in Boston SIMPLUS Multi-Action Solution were conducted in accordance with the requirements of ISO 10993; Biological Evaluation of Medical Devices, Part 10: Tests for Irritation and Sensitization. The test solution did not produce significant ocular irritation. All test requirements were met.
The results of these tests demonstrate that the product is not toxic.
Stability/Sterility
Stability studies were performed to evaluate the effects of various temperatures on the physical, microbiological and chemical properties of various lots of Boston SIMPLUS Multi-Action Solution. These studies are on-going. To date, all data indicates that the test product meets its specifications.
Cleaning Studies
The cleaning efficacy of Boston SIMPLUS Multi-Action Solution was determined by a series of in-vitro studies. In addition, the returned clinical lenses were evaluated for cleanliness.
The Critical Micelle Concentration of the surfactant in Boston SIMPLUS Multi-Action Solution was evaluated and found acceptable.
2
Testing was performed to determine the cleaning ability of Boston SIMPLUS Multi-Action Solution on rigid gas permeable contact lenses. The first model employed a protein and lipid mixture deposition. The results of this model indicate that the test solution cleans equivalently to or better than the positive and negative controls. A second model employed a tenacious deposition of protein. The results of this model indicate that the test solution cleans better than the positive and negative controls.
Lens compatibility studies were performed to determine the average changes observed in the physical lens parameters of rigid gas permeable contact lenses when subjected to repeated cleaning cycles with Boston SIMPLUS Multi-Action Solution. The physical lens parameters tested within the specifications. The cosmetic appearance of both lens materials tested equivalent to their respected controls.
Lenses returned from the clinical study that were used with either the Test (Boston SIMPLUS Multi-Action Solution) or Control (Boston Simplicity Multi-Action Solution) regimens have been examined by Image Analysis for lens cleanliness and found to be substantially equivalent.
Microbiology Studies
A series of studies as provided in the Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products were completed to demonstrate the microbiological efficacy of Boston SIMPLUS Multi-Action Solution.
Microbiology testing included Preservative Efficacy with Rechallenge. Disinfection Efficacy-Stand Alone, Disinfection Efficacy-Stand Alone with Organic Soil and a Regimen Test. All results are satisfactory and indicate that the product meets FDA/ISO requirements.
Clinical Studies
A multi-site randomized, controlled clinical study was conducted to evaluate the safery and efficacy of Boston SIMPLUS Multi-Action Solution employing a regimen that requires the user to rub lenses after the disinfection cycle. The Control solution was Boston Simplicity Multi-Action Solution traditional rub and rinse steps.
Patients were instructed to wear their lenses on a daily wear basis with no scheduled replacements and to clean and disinfect them in accordance with the provided directions for use. Evaluations included visual acuity, lens surface characteristics, and physiological response. The safety endpoint of no statistically significant difference in the incidence rate of any Grade 2 or greater slit lamp findings between the Test and Control was satisfied. The efficacy endpoint of statistical equivalence in the proportion of lens visual acuities at the level of 20/40 or better was met.
3
Both solutions demonstrated clinically acceptable lens cleanliness. Safety and efficacy were demonstrated. Boston SIMPLUS Multi-Action Solution is substantially equivalent to Boston Simplicity Multi-Action Solution.
Substantial Equivalence
Boston SIMPLUS Multi-Action Solution for use with rigid gas permeable contact lenses is substantially equivalent to Boston Simplicity Multi-Action Solution, Bausch & Lomb ReNu Multi-Purpose Solution and Alcon Unique pH Solution.
Boston SIMPLUS Multi-Action Solution will be sold in plastic bottles as a sterile solution; each bottle will be marked by a lot number and expiration date.
4
Image /page/4/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of an eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAY - 2 2003
Bausch & Lomb Incorporated c/o Jennifer B. Murray Associate Manager 1400 N. Goodman Street Rochester, NY 14609
Re: K024289
Trade/Device Name: Boston SIMPLUS Multi-Action Solution Regulation Number: 21 CFR 886.5918 Regulation Name: Rigid gas permeable contact lens care products Regulatory Class: Class II Product Code: MRC Dated: April 21, 2003 Received: April 22, 2003
Dear Ms. Murray:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
5
Page 2 - Jennifer B. Murray
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
A. helyi kirendbal
A. Ralph Rosenthal, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Polymer Technology a Bausch & Lomb company 1400 North Goodman Street Rochester, NY 14609
Indications for Use Statement
510(k) Number (if known): K024289
Device Name: Boston® SIMPLUS Multi-Action Solution
Indications for Use:
Boston SIMPLUS Multi-Action Solution is indicated for use in cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use __
OR
Over-The-Counter-Use
(Division Sign-Off) Division of Ophthalmic Ear, Nose and Throat Devises
April
510(k) Number K024289